Peter Ordentlich

Peter Ordentlich, Ph.D. co-founded the company in October 2005 and has served as our Chief Technology Officer since November 2013. Dr. Ordentlich previously served as our Vice President, Translational Medicine from January 2012 to October 2013, our Executive Director, Translational Science from January 2011 to December 2011, and our Director, Scientific Affairs and Strategic Alliances from January 2008 to December 2010. Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc. Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.

Peter Ordentlich is the Chief Scientific Officer and Founder at Syndax Pharmaceuticals, based in United States, North America. With a background in Biotechnology, Peter Ordentlich has a rich history of leadership and innovation.Peter Ordentlich studied Ph. D Immunology at University of Pennsylvania. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.